Molecular mechanisms of sglt2 inhibitor on cardiorenal protection

Yi Chou Hou; Cai Mei Zheng; Tzung Hai Yen; Kuo Cheng Lu

doi:10.3390/ijms21217833

Molecular mechanisms of sglt2 inhibitor on cardiorenal protection

Yi Chou Hou, Cai Mei Zheng, Tzung Hai Yen, Kuo Cheng Lu

Research output: Contribution to journal › Review article › peer-review

52 Citations (Scopus)

Abstract

The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre-and post-glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.

Original language	English
Article number	7833
Pages (from-to)	1-25
Number of pages	25
Journal	International journal of molecular sciences
Volume	21
Issue number	21
DOIs	https://doi.org/10.3390/ijms21217833
Publication status	Published - Nov 1 2020

Keywords

Cardiovascular disease
Chronic kidney disease
Diabetes mellitus
SGLT2

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms21217833

Cite this

@article{312aef92437645d4b74dd838e295ef91,

title = "Molecular mechanisms of sglt2 inhibitor on cardiorenal protection",

abstract = "The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre-and post-glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.",

keywords = "Cardiovascular disease, Chronic kidney disease, Diabetes mellitus, SGLT2",

author = "Hou, {Yi Chou} and Zheng, {Cai Mei} and Yen, {Tzung Hai} and Lu, {Kuo Cheng}",

note = "Funding Information: Funding: This study is funded by Cardinal Tien Hospital (Grant number: CTH-105B-226) Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = nov,

day = "1",

doi = "10.3390/ijms21217833",

language = "English",

volume = "21",

pages = "1--25",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "MDPI AG",

number = "21",

}

TY - JOUR

T1 - Molecular mechanisms of sglt2 inhibitor on cardiorenal protection

AU - Hou, Yi Chou

AU - Zheng, Cai Mei

AU - Yen, Tzung Hai

AU - Lu, Kuo Cheng

PY - 2020/11/1

Y1 - 2020/11/1

N2 - The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre-and post-glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.

AB - The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre-and post-glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Diabetes mellitus

KW - SGLT2

UR - http://www.scopus.com/inward/record.url?scp=85094140640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094140640&partnerID=8YFLogxK

U2 - 10.3390/ijms21217833

DO - 10.3390/ijms21217833

M3 - Review article

C2 - 33105763

AN - SCOPUS:85094140640

SN - 1661-6596

VL - 21

SP - 1

EP - 25

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 21

M1 - 7833

ER -

Molecular mechanisms of sglt2 inhibitor on cardiorenal protection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this